Sarepta Therapeutics, INC. (SRPT) — 8-K Filings

8-K Filings (17)

• 8-K Filing — Dec 19, 2025
• Sarepta Therapeutics Files 8-K on Equity Sales — Dec 11, 2025 Risk: medium
  On December 10, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included information on
• Sarepta Therapeutics Files 8-K: Director Changes & Compensation Updates — Dec 8, 2025 Risk: medium
  On December 7, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing the departure of a director, the election of new directors, and updates to executi
• 8-K Filing — Nov 3, 2025
• Sarepta Therapeutics Enters Material Agreement — Aug 29, 2025 Risk: medium
  On August 28, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Sarepta Therapeutics Reports Unregistered Equity Sales — Aug 21, 2025 Risk: medium
  On August 18, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates a transaction occurre
• Sarepta Therapeutics Announces Executive and Director Changes — Aug 13, 2025 Risk: medium
  On August 12, 2025, Sarepta Therapeutics, Inc. announced changes in its executive and director roles. The company elected new directors and appointed new office
• Sarepta Therapeutics Files 8-K Report — Jul 21, 2025 Risk: low
  On July 21, 2025, Sarepta Therapeutics, Inc. filed an 8-K report. The filing pertains to 'Other Events' and does not disclose specific financial transactions or
• Sarepta Acquires Roche's DMD Assets for $1.1B — Jul 16, 2025 Risk: medium
  Sarepta Therapeutics, Inc. announced on July 14, 2025, that it has entered into a definitive agreement to acquire certain assets from Roche related to its Duche
• Sarepta Therapeutics Announces Board and Compensation Changes — Jun 6, 2025 Risk: medium
  Sarepta Therapeutics, Inc. announced on June 5, 2025, changes in its board of directors and executive compensation arrangements. The filing also details the sub
• Sarepta Therapeutics Files 8-K on Financials — Feb 26, 2025 Risk: low
  On February 26, 2025, Sarepta Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Sarepta Therapeutics Enters Material Definitive Agreement — Feb 14, 2025 Risk: medium
  On February 13, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obl
• Sarepta Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Sarepta Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Sarepta Therapeutics Enters Material Definitive Agreement — Nov 26, 2024 Risk: medium
  On November 24, 2024, Sarepta Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, s
• Sarepta Therapeutics Appoints New Director — Sep 16, 2024 Risk: low
  Sarepta Therapeutics, Inc. announced on September 12, 2024, a change in its board of directors. Specifically, Dr. Richard S. Levitan has been appointed as a Cla
• Sarepta Therapeutics Appoints New CMO, Elects Directors — Jun 7, 2024 Risk: low
  Sarepta Therapeutics, Inc. announced on June 6, 2024, the appointment of Dr. Michael L. Johnson as Chief Medical Officer and the election of Dr. Johnson and Ms.
• Sarepta Files 8-K on Operations & Financial Condition — Jan 8, 2024
  Sarepta Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD d

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX